A comprehensive view of Valneva SE. This page highlights a small sample of our full coverage.
For real-time access, please log in to your R&D/Patents Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Pfizer investing US$95M in vaccine company Valneva SE; investment supports strategic partnership between both companies to develop Lyme disease vaccine
Published: June 22, 2022 by Marketline - Deals
Valneva, Pfizer report positive Phase 2 pediatric data for VLA15 Lyme disease vaccine candidate; VLA15 is the only Lyme disease vaccine currently in clinical development, with Lyme disease affecting 476,000 people in US, 130,000 people in Europe annually
Published: April 29, 2022 by Pfizer Inc.
Valneva Scotland announces research funding of up to £20M from Scotland’s national economic development agency; initial grant of £12.5M supports development related to Valneva’s inactivated, whole virus COVID-19 vaccine candidate
Published: February 22, 2022 by Valneva SE
Valneva announces its inactivated COVID-19 vaccine candidate neutralizes Omicron variant in Phase 1/2 trial; 100% of participants showed antibodies against ancestral virus and Delta variant, 87% had antibodies against Omicron
Published: January 19, 2022 by Valneva SE
Valneva announces advance purchase agreement with the European Commission to supply up to 60 million doses of inactivated COVID-19 vaccine candidate over two years; company expects to deliver 24.3 million doses during Q2 and Q3 of 2022
Published: November 23, 2021 by GlobeNewswire Europe

Ask us about our R&D/Patents market view

Trending Chart

Interactive chart with headline count